CNTX

Context Therapeutics Inc

0.6537

Jul 02 • 04:00PM ET +0.0454 (7.46%)

Healthcare Biotechnology USA Micro NASD

Peers: KPTI OABI CAMP HUMA RNA TENX TNXP UNCY WHWK MIST

| Held by: VTI IWM VXF IWO IWC RSSL ITWO UWM URTY HDG

Scroll to Statements

Index	RUT
Market Cap	60.06M
Enterprise Value	5.81M
Income	-40.23M
Sales	0.00M
Book/sh	0.57
Cash/sh	0.59
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Oct 20, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.15
P/C	1.10
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.92
Current Ratio	8.92
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.43
EPS next Y	-0.43
EPS next Q	-0.09
EPS this Y	-3.22%
EPS next Y	-10.27%
EPS next 5Y	-11.58%
EPS past 3/5Y	25.81% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-24.56%
Sales Y/Y TTM	-
EPS Q/Q	-89.60%
Sales Q/Q	-
Earnings	May 06 AMC
EPS/Sales Surpr.	19.14% -

Insider Own	9.93%
Insider Trans	0.00%
Inst Own	57.42%
Inst Trans	-0.83%
ROA	-52.99%
ROE	-56.19%
ROIC	-76.88%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-31.98%
SMA50	-64.36%
SMA200	-63.12%
Trades

Shs Outstand	91.88M
Shs Float	82.76M
Short Float	1.03%
Short Ratio	0.46
Short Interest	0.85M
52W High	3.62 -81.94%
52W Low	0.55 19.92%
Volatility	10.88% 16.78%
ATR (14)	0.14
RSI (14)	25.96
Beta	1.74
Rel Volume	1.39
Avg Volume	1.85M
Volume	2,578,472

Perf Week	16.73%
Perf Month	-72.99%
Perf Quarter	-75.33%
Perf Half Y	-49.72%
Perf YTD	-55.53%
Perf Year	3.47%
Perf 3Y	-59.14%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	5.44
Prev Close	0.61
Price	0.65
Change	7.46%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Initiated	Guggenheim	Buy	$5
Apr-21-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	JMP Securities	Mkt Outperform	$4
Nov-25-24	Initiated	D. Boral Capital	Buy	$9
May-16-24	Initiated	Piper Sandler	Overweight	$4.50

Jun-15-26 05:20PM	CNTX Hits Worst Day In History After Ovarian Cancer Trial Data But Analysts See Buying Opportunity In Dip (Stocktwits) -51.14%
06:30AM	Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 (GlobeNewswire)
Jun-09-26 04:10PM	Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.11%
May-27-26 07:30AM	Context Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +13.31%
May-18-26 06:45AM	Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 (GlobeNewswire)
04:18PM	Loading…
May-06-26 04:18PM	Context Therapeutics Reports First Quarter 2026 Operating and Financial Results (GlobeNewswire)
Apr-08-26 08:00AM	Neogen Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary (Business Wire)
Apr-02-26 07:30AM	Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Mar-23-26 04:16PM	Context Therapeutics Reports Full Year 2025 Operating and Financial Results (GlobeNewswire) +5.30%
Mar-19-26 07:30AM	Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
Mar-08-26 04:02PM	Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference (MarketBeat)
Feb-09-26 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-16-26 04:05PM	Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.26% +6.94%
Nov-14-25 12:04AM	BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... (GuruFocus.com)
Nov-07-25 07:30AM	Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting (GlobeNewswire)
04:15PM	Loading…
Nov-05-25 04:15PM	Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results (GlobeNewswire) -5.31%
Oct-28-25 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-06-25 07:30AM	Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire) +10.00%
Oct-03-25 04:15PM	Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.03%
Aug-27-25 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-06-25 04:11PM	Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results (GlobeNewswire)
Jul-25-25 12:22PM	Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 (Insider Monkey)
Jun-02-25 07:30AM	Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting (GlobeNewswire)
May-29-25 07:30AM	Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer (GlobeNewswire)
May-12-25 04:38PM	Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.14%
May-07-25 04:09PM	Context Therapeutics Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire)
May-05-25 04:05PM	Context Therapeutics Announces Chief Medical Officer Transition (GlobeNewswire)
Apr-30-25 07:30AM	Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting (GlobeNewswire)
Apr-21-25 07:40AM	Bet on These 5 Top-Ranked Stocks With Rising P/E (Zacks)
Apr-09-25 07:30AM	Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 (GlobeNewswire)
08:51AM	Loading…
Apr-04-25 08:51AM	Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos (Zacks) -16.68%
Apr-03-25 08:11AM	Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains (Zacks) +5.58%
Apr-01-25 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.95%
Mar-26-25 04:02PM	Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -8.57% -6.88%
Mar-20-25 04:22PM	Context Therapeutics Reports Full Year 2024 Operating and Financial Results (GlobeNewswire) -5.98%
Feb-24-25 05:05PM	Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-15-25 11:29AM	Context doses first subject in Phase I cancer trial of CTIM-76 (Clinical Trials Arena)
Jan-14-25 04:58PM	Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 (GlobeNewswire)
Jan-13-25 07:30AM	Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors (GlobeNewswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Nov-06-24 04:06PM	Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) -5.86%
Oct-23-24 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire) +11.50%
Oct-16-24 07:30AM	Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +5.13%
Sep-23-24 07:30AM	BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody (GlobeNewswire) -7.96%
Sep-12-24 09:40AM	Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? (Zacks)
Sep-04-24 07:30AM	Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors (GlobeNewswire)
Aug-27-24 09:40AM	Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? (Zacks)
Aug-07-24 04:17PM	Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire)
Aug-01-24 07:30AM	Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations (GlobeNewswire)
Jul-10-24 07:30AM	Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 (GlobeNewswire)
May-30-24 06:11AM	Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight (InvestorPlace)
May-22-24 08:50PM	The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains (InvestorPlace)
May-20-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice (Zacks)
May-14-24 12:00PM	Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why (Zacks)
May-08-24 11:56PM	CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.23%
04:06PM	Context Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
May-02-24 07:31AM	Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 (GlobeNewswire) +28.68%
07:30AM	Context Therapeutics Announces $100 Million Private Placement (GlobeNewswire)
Apr-01-24 07:30AM	Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers (GlobeNewswire)
Mar-21-24 01:53PM	CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.96%
07:43AM	Context Therapeutics Reports Full Year 2023 Operating and Financial Results (GlobeNewswire)
Nov-09-23 04:15PM	Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire)
Oct-31-23 09:00AM	Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +13.64%
Sep-27-23 09:00AM	Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +16.22%
Aug-10-23 02:19PM	Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update (News Direct) +10.64%
Aug-09-23 04:10PM	Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire) -9.62%
Aug-01-23 07:30AM	Context Therapeutics to Participate in Two August 2023 Investor Conferences (GlobeNewswire) +7.27%
Jun-13-23 01:34PM	Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update (News Direct)
Jun-03-23 08:27AM	Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely? (Simply Wall St.)
May-10-23 04:39PM	Context Therapeutics Reports First Quarter 2023 Operating and Financial Results (GlobeNewswire) -6.37%
Apr-24-23 12:01PM	Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting (News Direct)
Apr-18-23 10:15AM	Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference (ACCESSWIRE)
Apr-04-23 12:00PM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023 (GlobeNewswire)
Apr-03-23 07:30AM	Context Therapeutics to Participate in Two April 2023 Investor Conferences (GlobeNewswire) +5.85%
Mar-22-23 05:08PM	Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates (GlobeNewswire) -7.59%
Mar-15-23 07:30AM	Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Feb-13-23 08:52AM	UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX) (GlobeNewswire)
Feb-10-23 01:36PM	Lab Notes: Center for Breakthrough Medicines expands offerings; Researchers identify key 'gene signature' (American City Business Journals)
Feb-07-23 12:21PM	Context Therapeutics announces positive responses in Phase 2 OATH clinical trial (News Direct)
Feb-06-23 07:30AM	Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer (GlobeNewswire) +5.27%
Jan-31-23 07:30AM	Context Therapeutics Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer (GlobeNewswire) +55.20%
Jan-09-23 07:30AM	Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers (GlobeNewswire) +8.32%
Jan-04-23 07:30AM	Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones (GlobeNewswire) +9.79%
Dec-08-22 07:30AM	Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer (GlobeNewswire) -28.42%
Nov-29-22 07:30AM	Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors (GlobeNewswire)
Nov-27-22 07:36AM	Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-21-22 09:11AM	Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-22 04:14PM	Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Oct-20-22 07:30AM	Context Therapeutics to Participate in the ThinkEquity Conference (Newsfile)
Sep-27-22 11:41AM	Context Therapeutics halting 'noncritical R&D' spending to extend cash runway (American City Business Journals)
07:30AM	Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024 (GlobeNewswire)
Sep-06-22 12:50PM	A number of insiders bought Context Therapeutics Inc. (NASDAQ:CNTX) stock last year, which is great news for shareholders (Simply Wall St.)
07:30AM	Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 04:01PM	Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +9.73%
Aug-02-22 10:49AM	Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination (PR Newswire) +5.82%
Jul-05-22 09:22PM	'I wanted to build it here': Life sciences startup leaders talk about challenges of growing in Philadelphia (American City Business Journals)
May-15-22 10:12AM	Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-11-22 04:01PM	Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -5.15% +6.98%

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Co-FounderMr. Martin A. Lehr

CFO & TreasurerMs. Jennifer Minai-Azary

J.D.Mr. Alex C. Levit Esq.

Senior Vice President of OperationsMr. Christopher Beck M.B.A.

Associate Director of AccountingMr. Jeffrey Liebman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

CNTX

Context Therapeutics Inc

Upgrade your Finviz experience